I know I didn't post the statements from the cardiology assessment team here but had indicated that they mentioned the potential risks. One such comment among 38 that said the same thing:
C18H26ClN3O both with the inclusion and exclusion of macrolide will induce in portions of the population abnormal arrhythmia. The absence of CT (Clinical Trials) will likely provide dangerous anecdotal outcomes if a placebo and control group is not used. Turns out cardiologists know more about human hearts than people who have never even seen a human heart but instead read excerpts from the internet.
The initial study referenced by the White House was the result of 108 vaccinated adults. Again that's 108.
The latest study consists of 671 hospitals in six continents.
Date span: Dec 20, 2019, and April 14, 2020.
96,032 patients.
Mean age 53.8 years, 46.3% female
All confirmed laboratory SARS-COV-2 with chloroquine treatment within 48 hours.
Patients who received remdesivir were excluded.
1868 received chloroquine: 3783 received chloroquine with a macrolide
3016 received hydroxychloroquine: 6221 received hydroxychloroquine with a macrolide.
81 144 patients were in the control group.
10 698 patients died in hospital = 11.1%
Control group mortality = 9.3%
De-novo ventricular arrhythmia during hospitalization increased slightly with the use of both Chloroquine/Hydroxychloroquine with or without macrolides.
Specific issues were found, and a Cox model was utilized:
“
A Cox proportional hazards model was fit for time to death, controlling for treatment group and potential confounders (age ≥65 years, sex, hospital, diabetes, chronic lung disease, cardiovascular disease [CVD, including hypertension, coronary artery disease, congestive heart failure], respiratory rate >22/min, O2 saturation <90%, abnormal chest imaging findings, aspartate aminotransferase [AST]>40 U/L, and elevated creatinine levels) based on a priori plausibility, documented associations with death or hydroxychloroquine administration from previous studies, bivariate associations within our data, ruling out collinearity using condition indices, and missingness of less than 10%"
https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1473309920302966?r...https://jamanetwork.com/journals/jama/fullarticle/2766117 Now this information, open for peer review, is for 96 thousand patients and includes a control group. Hydroxychloroquine has, at this time, an increased rate of causing heart-problems leading to death.
This doesn’t mean Hydroxychloroquine isn’t somewhat effective in certain capacities, in specific demographics, but it does outline why a “study” of 108 patients is not enough to go around saying any drug is going to help.